Skip to main navigation
Close
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Breadcrumb
Association for Accessible Medicines
Resources
Blog
Blog
Share
Blog
Apr 27, 2017
| Erica Klinger
Group Letter in Support of CREATES Act
Blog
Apr 17, 2017
| Erica Klinger
REMS Abuse Impeding Patient Access to Generic Drugs – Myths and Facts
Blog
Apr 16, 2017
| Model B
What They Are Saying - Blocking Access to Samples
Blog
Apr 11, 2017
| Erica Klinger
Learn to manage the GDUFA landscape at our CMC Workshop
Blog
Apr 10, 2017
| Erica Klinger
Veto Maryland House Bill 631, Which Would Harm Patients by Chilling Generic Drug Competition
Blog
Apr 6, 2017
| Erica Klinger
AAM Group Letter of Support for FAST Generics Act
Blog
Mar 28, 2017
| Erica Klinger
Recapping: The Future for Biosimilars
Blog
Mar 10, 2017
| Erica Klinger
The Future of Biosimilars – An Atlantic Policy Briefing
Blog
Feb 8, 2017
| Erica Klinger
2016 AAM Annual Report
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2024
GRx+Biosims 2023
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action